Palatin Technologies | Home
At Palatin, we drive our culture with science. Our employees have unparalleled expertise related to the melanocortin system allowing them to develop potent, selective treatments for patients with unmet medical needs.
Palatin Technologies | Pipeline
Palatin is developing a truly novel class of drugs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve disease inflammation in the eye.
Palatin Technologies | About Us
Robert has successfully managed several drug programs, including Palatin’s development of Vyleesi ® from phase 2 through NDA submission and FDA approval in 2019 as the only as-needed treatment for hypoactive sexual desire disorder (HSDD). Robert oversees all of Palatin’s drug development programs as well as leads clinical operations.
Palatin Technologies | Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 …
2024年2月28日 · Palatin will host a conference call and audio webcast on February 28, 2024, at 8:30 a.m. Eastern Time to discuss the PL9643 Phase 3 clinical study results in greater detail. Individuals interested in listening to the conference call live can dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 295124.
Palatin Technologies | Our Science
The melanocortin system is mediated by a family of five related receptors that are essential to the body’s control of inflammation, immune response, metabolism, steroid hormone production, and sexual function. This expansive range of effects can …
Palatin Technologies | Webcasts
Palatin Technologies Third Quarter Fiscal Year 2023 Financial Teleconference and Webcast
Palatin Technologies | Investors
In this section, you will find information regarding the financial highlights of Palatin. For your convenience, we provide a library of press releases, events, and webcasts, as well as prefiltered links to the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database.
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated …
2023年8月10日 · Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential.
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ...
2024年9月30日 · CRANBURY, N.J., Nov. 14, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced operating and financial results for its fiscal first quarter ended September 30, 2024.